www.hivandhepatitis.com

Skip to content

Back HCV Treatment

AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis

Details: Category: HCV Treatment; Published on Tuesday, 31 October 2017 00:00; Written by Liz Highleyman

Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

Subcategories

Page 8 of 643

Hepatitis C Topics